Sunbird Bio-Energy

Sunbird Bio is a clinical-stage biotechnology company developing next-generation blood-based diagnostic tests for neurological disorders and cancer. The company's proprietary APN (Aggregated Protein Nanoparticle) platform enables the highly sensitive detection of protein aggregates, such as amyloid-beta and tau, which are critical biomarkers for Alzheimer's disease. By focusing on extracellular vesicle (EV) analysis, Sunbird Bio aims to provide earlier and more accurate diagnoses compared to traditional imaging or cerebrospinal fluid tests. The company was formed through a merger with Glympse Bio and maintains operations in both Singapore and Cambridge, Massachusetts. Sunbird Bio is currently advancing its lead diagnostic programs through clinical validation to support drug development and patient care.